A universal plasma metabolites-derived signature predicts cardiovascular disease risk in MAFLDOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study sought a very early way to predict cardiovascular disease (CVD) risk in metabolic associated fatty liver disease (MAFLD), before pathological damage appears. It profiled stool microbiomes and plasma metabolites together. Gut bacteria were characterized by 16S rDNA sequencing and plasma metabolites by untargeted metabolomics. Differential abundance analysis and a random forest machine learning algorithm identified discriminatory features. The team built and validated a predictive model combining metabolites with clinical parameters, and tested a key metabolite in vitro and in vivo.
Who was studied?
The cohort was 196 well-characterized participants, spanning normal controls, simple MAFLD patients, MAFLD patients with carotid artery pathological changes, and MAFLD patients with diagnosed coronary artery disease. This was a case-control human study. Participants included both men and women across middle-aged and older adults. Carotid ultrasound measured mean intima-media thickness (IMT) to stage vascular change. Model performance was checked in a proband cohort and a separate validation cohort.
What were the most important findings?
MAFLD patients with CVD risk showed increased Clostridia and higher Firmicutes-to-Bacteroidetes ratios. Faecalibacterium was negatively correlated with mean IMT, total cholesterol, and triglycerides, while Megamonas, Bacteroides, Parabacteroides, and Escherichia rose with worsening pathology. These patients had lower lithocholic acid taurine conjugate and higher ethylvanillin propylene glycol acetal, both tied to Ruminococcus and Gemmiger. A model combining the metabolite signature with 9 clinical parameters accurately distinguished CVD risk. Citral was the single most important discriminative metabolite marker.
What are the greatest implications of this study?
The findings suggest that gut microbes and plasma metabolites diverge early in MAFLD patients heading toward cardiovascular disease, offering a potential way to flag risk before vascular damage forms. The authors present this as a predictive signature, not a proven cause. If validated further, a metabolite-plus-clinical model could enable earlier intervention than carotid ultrasound alone. Because the design is case-control and the microbiome associations are correlational, causal roles for specific taxa or metabolites remain to be established in larger prospective studies.